DR. IAN DENISON SCHNADIG M.D.
Prescription History 1467664839
Internal Medicine - Hematology & Oncology in Tualatin, OR


Quality Rating: 92.56 out of 100 score

NPI Status: Active since May 05, 2007

Contact Information

19260 SW 65TH AVE
SUITE 435
TUALATIN, OR
ZIP 97062
Phone: (503) 692-2032
Fax: (503) 692-4450

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. IAN DENISON SCHNADIG M.D., an active Hematology & Oncology specialist practicing in Tualatin, OR. Our medical registry currently tracks 29 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 1,294 documented patient claims. Among these therapy options, the most frequently utilized medication is Abiraterone Acetate, which accounts for 406 claims alone.


Abiraterone Acetate

Generic Formulation: Abiraterone AcetateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 406
30-Day Fills 412.0
Days Supply 12,345
OR State Average Benchmarks
Peer Average Claims50.0
Peer Average 30-Day Fills58.7
Peer Average Days Supply1,751
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 712.0% higher than the standard regional baseline profile for OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $775,843.75 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,910.95

State Avg Cost Per Claim

$1,917.45

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER.

Therapeutic Applications

This medication is used to treat prostate cancer. Abiraterone belongs to a class of drugs known as anti-androgens (anti-testosterone). Testosterone, a natural hormone, helps prostate cancer to grow and spread. Abiraterone works by blocking the production of testosterone, thereby slowing the growth and spread of prostate cancer. This medication should not be given to women or children.

Acyclovir

Generic Formulation: AcyclovirSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 39.0
Days Supply 1,170
OR State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills40.7
Peer Average Days Supply1,075
Conservative Utilization

This provider writes prescriptions for this formulation 45.8% less frequently than the standard regional baseline metric for practitioners inside OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $528.72 across this reporting matrix range.

Provider Avg Cost Per Claim

$40.67

State Avg Cost Per Claim

$22.21

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.

Therapeutic Applications

Acyclovir is used to treat infections caused by certain types of viruses. It treats cold sores around the mouth (caused by herpes simplex), shingles (caused by herpes zoster), and chickenpox. This medication is also used to treat outbreaks of genital herpes. In people with frequent outbreaks, acyclovir is used to help reduce the number of future episodes. Acyclovir is an antiviral drug. However, it is not a cure for these infections. The viruses that cause these infections continue to live in the body even between outbreaks. Acyclovir decreases the severity and length of these outbreaks. It helps the sores heal faster, keeps new sores from forming, and decreases pain/itching. This medication may also help reduce how long pain remains after the sores heal. In addition, in people with a weakened immune system, acyclovir can decrease the risk of the virus spreading to other parts of the body and causing serious infections.

Bicalutamide

Generic Formulation: BicalutamideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 41
30-Day Fills 119.0
Days Supply 3,570
OR State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills39.7
Peer Average Days Supply1,166
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 95.2% higher than the standard regional baseline profile for OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,519.22 across this reporting matrix range.

Provider Avg Cost Per Claim

$85.83

State Avg Cost Per Claim

$38.80

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Bicalutamide is used to treat prostate cancer. This medication works by blocking the action of male hormones in the prostate, slowing the growth of cancer cells. This medication should not be used in women and children.

Cabometyx

Generic Formulation: Cabozantinib S-MalateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 22
30-Day Fills 22.0
Days Supply 660
OR State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills16.7
Peer Average Days Supply494
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 37.5% more claims than the standard regional baseline profile for OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $583,477.56 across this reporting matrix range.

Provider Avg Cost Per Claim

$26,521.71

State Avg Cost Per Claim

$23,350.32

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat various types of cancer (including kidney, thyroid, liver cancer). Cabozantinib belongs to a class of drugs known as tyrosine kinase inhibitors. It works by slowing or stopping the growth of cancer cells.

Dexamethasone

Generic Formulation: DexamethasoneSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 22
30-Day Fills 37.4
Days Supply 947
OR State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills37.4
Peer Average Days Supply615
Conservative Utilization

This provider writes prescriptions for this formulation 33.3% less frequently than the standard regional baseline metric for practitioners inside OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,181.87 across this reporting matrix range.

Provider Avg Cost Per Claim

$53.72

State Avg Cost Per Claim

$18.56

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anti-inflammatory 9-fluoro-glucocorticoid.

Therapeutic Applications

Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer, and immune system disorders. It is also used as a test for an adrenal gland disorder (Cushing's syndrome). Dexamethasone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Eliquis

Generic Formulation: ApixabanSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 28.0
Days Supply 840
OR State Average Benchmarks
Peer Average Claims61.0
Peer Average 30-Day Fills108.1
Peer Average Days Supply3,150
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 82.0% less volume than the regional standard for practitioners inside OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $15,238.30 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,385.30

State Avg Cost Per Claim

$912.24

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Erleada

Generic Formulation: ApalutamideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 34
30-Day Fills 34.0
Days Supply 1,020
OR State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills28.9
Peer Average Days Supply867
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $447,230.44 across this reporting matrix range.

Provider Avg Cost Per Claim

$13,153.84

State Avg Cost Per Claim

$14,361.91

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apalutamide is used to treat men with prostate cancer. This medication belongs to a class of drugs known as anti-androgens (anti-testosterone). It works by blocking the effects of testosterone to slow the growth and spread of prostate cancer.

Hydrochlorothiazide

Generic Formulation: HydrochlorothiazideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 29.1
Days Supply 873
OR State Average Benchmarks
Peer Average Claims62.0
Peer Average 30-Day Fills162.7
Peer Average Days Supply4,868
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 82.3% less volume than the regional standard for practitioners inside OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $66.90 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.08

State Avg Cost Per Claim

$6.03

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.

Therapeutic Applications

This medication is used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. Hydrochlorothiazide belongs to a class of drugs known as diuretics/water pills. It works by causing you to make more urine. This helps your body get rid of extra salt and water. This medication also reduces extra fluid in the body (edema) caused by conditions such as heart failure, liver disease, or kidney disease. This can lessen symptoms such as shortness of breath or swelling in your ankles or feet.

Hydroxyurea

Generic Formulation: HydroxyureaSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 24
30-Day Fills 71.7
Days Supply 2,150
OR State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills72.8
Peer Average Days Supply2,163
Conservative Utilization

This provider writes prescriptions for this formulation 35.1% less frequently than the standard regional baseline metric for practitioners inside OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,530.76 across this reporting matrix range.

Provider Avg Cost Per Claim

$63.78

State Avg Cost Per Claim

$38.81

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Therapeutic Applications

This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas).

Ibrance

Generic Formulation: PalbociclibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 308
OR State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills28.0
Peer Average Days Supply773
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 59.3% less volume than the regional standard for practitioners inside OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $157,818.64 across this reporting matrix range.

Provider Avg Cost Per Claim

$14,347.15

State Avg Cost Per Claim

$14,539.84

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Palbociclib is used to treat a certain type of breast cancer. It works by slowing or stopping the growth of cancer cells.

Imbruvica

Generic Formulation: IbrutinibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 35
30-Day Fills 35.0
Days Supply 980
OR State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills29.6
Peer Average Days Supply843
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $581,136.05 across this reporting matrix range.

Provider Avg Cost Per Claim

$16,603.89

State Avg Cost Per Claim

$14,708.05

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain cancers (such as mantle cell or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom's macroglobulinemia). Ibrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. Ibrutinib is also used to treat a certain problem that may occur after a stem cell transplant (chronic graft versus host disease). It works by weakening your body's defense system (immune system).

Inlyta

Generic Formulation: AxitinibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 18
30-Day Fills 18.0
Days Supply 540
OR State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills16.9
Peer Average Days Supply503
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $347,050.96 across this reporting matrix range.

Provider Avg Cost Per Claim

$19,280.61

State Avg Cost Per Claim

$17,253.56

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzamide and indazole derivative that acts as a TYROSINE KINASE inhibitor of the VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR. It is used in the treatment of advanced RENAL CELL CARCINOMA.

Therapeutic Applications

This medication is used to treat kidney cancer. Axitinib works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as tyrosine kinase inhibitors.

Jakafi

Generic Formulation: Ruxolitinib PhosphateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 19
30-Day Fills 19.0
Days Supply 570
OR State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills29.7
Peer Average Days Supply888
Conservative Utilization

This provider writes prescriptions for this formulation 34.5% less frequently than the standard regional baseline metric for practitioners inside OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $267,791.15 across this reporting matrix range.

Provider Avg Cost Per Claim

$14,094.27

State Avg Cost Per Claim

$15,331.30

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain bone marrow disorders (myelofibrosis, polycythemia vera). It works by blocking your body from producing substances called growth factors. Growth factors cause cells to grow and divide, and cause the blood cell and spleen problems found in these disorders. Ruxolitinib belongs to a class of drugs known as kinase inhibitors. Though not a cure for these disorders, ruxolitinib may help with some of the symptoms, including abdominal discomfort, pain under left ribs, early feelings of fullness from meals, night sweats, itching, and bone/muscle pain. Ruxolitinib is also used to treat a certain problem that may occur after certain stem cell or bone marrow transplants (graft versus host disease). It works by weakening your body's defense system (immune system).

Letrozole

Generic Formulation: LetrozoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 22
30-Day Fills 61.5
Days Supply 1,846
OR State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills101.5
Peer Average Days Supply3,034
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 52.2% less volume than the regional standard for practitioners inside OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,083.43 across this reporting matrix range.

Provider Avg Cost Per Claim

$49.25

State Avg Cost Per Claim

$26.04

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Lisinopril

Generic Formulation: LisinoprilSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 31.0
Days Supply 930
OR State Average Benchmarks
Peer Average Claims112.0
Peer Average 30-Day Fills280.9
Peer Average Days Supply8,396
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 88.4% less volume than the regional standard for practitioners inside OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $66.36 across this reporting matrix range.

Provider Avg Cost Per Claim

$5.10

State Avg Cost Per Claim

$8.24

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.

Therapeutic Applications

Lisinopril is used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. It is also used to treat heart failure and to improve survival after a heart attack. Lisinopril belongs to a class of drugs known as ACE inhibitors. It works by relaxing blood vessels so blood can flow more easily.

Methylprednisolone

Generic Formulation: MethylprednisoloneSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
OR State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills23.4
Peer Average Days Supply205
Conservative Utilization

This provider writes prescriptions for this formulation 45.5% less frequently than the standard regional baseline metric for practitioners inside OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $300.12 across this reporting matrix range.

Provider Avg Cost Per Claim

$25.01

State Avg Cost Per Claim

$11.66

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A PREDNISOLONE derivative with similar anti-inflammatory action.

Therapeutic Applications

Methylprednisolone is used to treat conditions such as arthritis, blood disorders, severe allergic reactions, certain cancers, eye conditions, skin/kidney/intestinal/lung diseases, and immune system disorders. It decreases your immune system's response to various diseases to reduce symptoms such as swelling, pain, and allergic-type reactions. This medication is a corticosteroid hormone. Methylprednisolone may also be used with other medications in hormone disorders.

Olanzapine

Generic Formulation: OlanzapineSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.1
Days Supply 179
OR State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills47.5
Peer Average Days Supply1,338
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 73.2% less volume than the regional standard for practitioners inside OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $86.91 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.90

State Avg Cost Per Claim

$30.20

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzodiazepine derivative that binds SEROTONIN RECEPTORS; MUSCARINIC RECEPTORS; HISTAMINE H1 RECEPTORS; ADRENERGIC ALPHA-1 RECEPTORS; and DOPAMINE RECEPTORS. It is an antipsychotic agent used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER; and MAJOR DEPRESSIVE DISORDER; it may also reduce nausea and vomiting in patients undergoing chemotherapy.

Therapeutic Applications

Olanzapine is used to treat certain mental/mood conditions (such as schizophrenia, bipolar disorder). It may also be used in combination with other medication to treat depression. This medication can help to decrease hallucinations and help you to think more clearly and positively about yourself, feel less agitated, and take a more active part in everyday life. Olanzapine belongs to a class of drugs called atypical antipsychotics. It works by helping to restore the balance of certain natural substances in the brain. Talk to the doctor about the risks and benefits of treatment (especially when used by teenagers). See also Precautions section.

Omeprazole

Generic Formulation: OmeprazoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 27
30-Day Fills 81.0
Days Supply 2,430
OR State Average Benchmarks
Peer Average Claims83.0
Peer Average 30-Day Fills179.8
Peer Average Days Supply5,357
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 67.5% less volume than the regional standard for practitioners inside OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $328.15 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.15

State Avg Cost Per Claim

$15.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.

Therapeutic Applications

Omeprazole is used to treat certain stomach and esophagus problems (such as acid reflux, ulcers). It works by decreasing the amount of acid your stomach makes. It relieves symptoms such as heartburn, difficulty swallowing, and cough. This medication helps heal acid damage to the stomach and esophagus, helps prevent ulcers, and may help prevent cancer of the esophagus. Omeprazole belongs to a class of drugs known as proton pump inhibitors (PPIs). If you are self-treating with this medication, over-the-counter omeprazole products are used to treat frequent heartburn (occurring 2 or more days a week). Since it may take 1 to 4 days to have full effect, these products do not relieve heartburn right away. For over-the-counter products, carefully read the package instructions to make sure the product is right for you. Check the ingredients on the label even if you have used the product before. The manufacturer may have changed the ingredients. Also, products with similar brand names may contain different ingredients meant for different purposes. Taking the wrong product could harm you.

Oxycodone Hcl

Generic Formulation: Oxycodone HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 330
OR State Average Benchmarks
Peer Average Claims53.0
Peer Average 30-Day Fills53.9
Peer Average Days Supply956
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 69.8% less volume than the regional standard for practitioners inside OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $457.32 across this reporting matrix range.

Provider Avg Cost Per Claim

$28.58

State Avg Cost Per Claim

$18.69

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic derivative of CODEINE.

Therapeutic Applications

This medication is used to help relieve moderate to severe pain. Oxycodone belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain.

Pomalyst

Generic Formulation: PomalidomideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 392
OR State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills24.9
Peer Average Days Supply692
Conservative Utilization

This provider writes prescriptions for this formulation 41.7% less frequently than the standard regional baseline metric for practitioners inside OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $342,863.40 across this reporting matrix range.

Provider Avg Cost Per Claim

$24,490.24

State Avg Cost Per Claim

$21,886.16

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Pomalidomide is used to treat certain types of cancers (such as multiple myeloma, Kaposi sarcoma). It works by slowing or stopping the growth of cancer cells.

Prednisone

Generic Formulation: PrednisoneSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 362
30-Day Fills 490.8
Days Supply 14,579
OR State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills49.4
Peer Average Days Supply1,018
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 878.4% higher than the standard regional baseline profile for OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,831.82 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.82

State Avg Cost Per Claim

$8.28

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Prochlorperazine Maleate

Generic Formulation: Prochlorperazine MaleateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 22
30-Day Fills 28.0
Days Supply 601
OR State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills29.4
Peer Average Days Supply311
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $961.74 across this reporting matrix range.

Provider Avg Cost Per Claim

$43.72

State Avg Cost Per Claim

$17.26

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612)

Therapeutic Applications

This medication is used to treat severe nausea and vomiting from certain causes (for example, after surgery or cancer treatment). Prochlorperazine belongs to a class of drugs known as phenothiazines. This medication is not recommended for use in children younger than 2 years or in children going through surgery.

Revlimid

Generic Formulation: LenalidomideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 252
OR State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills36.5
Peer Average Days Supply980
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 66.7% less volume than the regional standard for practitioners inside OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $140,771.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$11,730.98

State Avg Cost Per Claim

$18,492.94

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA.

Therapeutic Applications

Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication.

Tamoxifen Citrate

Generic Formulation: Tamoxifen CitrateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 17
30-Day Fills 51.0
Days Supply 1,530
OR State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills102.9
Peer Average Days Supply3,069
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 61.4% less volume than the regional standard for practitioners inside OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $410.72 across this reporting matrix range.

Provider Avg Cost Per Claim

$24.16

State Avg Cost Per Claim

$39.45

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.

Therapeutic Applications

Tamoxifen is used to treat breast cancer. It is also used to reduce the chances of breast cancer in high-risk patients. This medication can block the growth of breast cancer. It works by interfering with the effects of estrogen in the breast tissue.

Tamsulosin Hcl

Generic Formulation: Tamsulosin HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 16
30-Day Fills 44.1
Days Supply 1,323
OR State Average Benchmarks
Peer Average Claims68.0
Peer Average 30-Day Fills157.0
Peer Average Days Supply4,678
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 76.5% less volume than the regional standard for practitioners inside OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $297.97 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.62

State Avg Cost Per Claim

$20.94

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Tamsulosin is used by men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It does not shrink the prostate, but it works by relaxing the muscles in the prostate and the bladder. This helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate often or urgently (including during the middle of the night). Tamsulosin belongs to a class of drugs known as alpha blockers. Do not use this medication to treat high blood pressure.

Venclexta

Generic Formulation: VenetoclaxSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 22
30-Day Fills 22.0
Days Supply 660
OR State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills20.8
Peer Average Days Supply593
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $308,202.46 across this reporting matrix range.

Provider Avg Cost Per Claim

$14,009.20

State Avg Cost Per Claim

$9,808.00

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of cancer (chronic lymphocytic leukemia-CLL, small lymphocytic lymphoma-SLL, acute myeloid leukemia-AML). Venetoclax is a drug that works by helping to slow or stop the growth of cancer cells.

Xarelto

Generic Formulation: RivaroxabanSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 28
30-Day Fills 62.0
Days Supply 1,860
OR State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills61.8
Peer Average Days Supply1,801
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $33,875.39 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,209.84

State Avg Cost Per Claim

$976.44

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Therapeutic Applications

Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban may be used in children to prevent blood clots from forming after a certain heart surgery (Fontan procedure). Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Xtandi

Generic Formulation: EnzalutamideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 21
30-Day Fills 21.0
Days Supply 630
OR State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills33.0
Peer Average Days Supply988
Conservative Utilization

This provider writes prescriptions for this formulation 34.4% less frequently than the standard regional baseline metric for practitioners inside OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $237,872.16 across this reporting matrix range.

Provider Avg Cost Per Claim

$11,327.25

State Avg Cost Per Claim

$12,583.47

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Enzalutamide is used to treat prostate cancer. This medication belongs to a class of drugs known as anti-androgens (anti-testosterone). It works by blocking the effects of testosterone to slow the growth and spread of prostate cancer.

Yonsa

Generic Formulation: Abiraterone Acet,submicronizedSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
OR State Average Benchmarks
Peer Average Claims45.0
Peer Average 30-Day Fills45.0
Peer Average Days Supply1,350
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 73.3% less volume than the regional standard for practitioners inside OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $121,332.47 across this reporting matrix range.

Provider Avg Cost Per Claim

$10,111.04

State Avg Cost Per Claim

$9,895.15

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat men with prostate cancer. Abiraterone belongs to a class of drugs known as anti-androgens (anti-testosterone). Testosterone, a natural hormone, helps prostate cancer to grow and spread. Abiraterone works by blocking the production of testosterone, which helps slow down the growth and spread of prostate cancer. This medication should not be used by women or children.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. IAN DENISON SCHNADIG M.D. provides transparency into local medical care patterns within Tualatin, OR.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology & Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.